glp-1 news 2025 october 16 Exploring the Side Effects of Receptor Agonist: To Ensure Its Optimal Positioning Mapping the effectiveness and risks

Its potentially a multi-billion-dollar opportunity to transition from generics leadership to value-driven innovation participation

This distinction has persisted despite evidence that obesity is a chronic disease requiring long-term pharmaceutical management

Weber MA, Mansfield TA, Cain VA, et al

[1] [8] They also act on receptors in the central nervous system, particularly in hypothalamic regions that regulate appetite and satiety

doi: 10.1016/j.conb.2025.103021, 49

Here, we sought to test these hypotheses by recruiting a cohort with obesity 19 either taking GLP-1 RAs or not and test breath alcohol content (BrAc) and subjective feelings after an alcohol challenge dose